Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 141

Sort by

Sort Order Select

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

Jiarna R. Zerella, Claire C. Homan, Peer Arts, Xuzhu Lin, Sam J. Spinelli, Parvathy Venugopal, Milena Babic, Peter J. Brautigan, Lynda Truong, Luis Arriola-Martinez, Sarah Moore, Rachel Hollins, Wendy T. Parker, Hung Nguyen, Karin S. Kassahn, Susan Branford, Simone Feurstein, Lise Larcher, Flore Sicre de Fontbrune, Serwet Demirdas, Sonja de Munnik, Hélène Antoine-Poirel, Benedicte Brichard, Sahar Mansour, Kristiana Gordon, Marcin W. Wlodarski, Ashwin Koppayi, Sara Dobbins, Pim G. N. J. Mutsaers, Kim E. Nichols, Ninad Oak, Desiree DeMille, Rong Mao, Ali Crawford, Julie McCarrier, Donald Basel, Josue Flores-Daboub, Michael W. Drazer, Kerry Phillips, Nicola K. Poplawski, Graeme M. Birdsey, Daniela Pirri, Pia Ostergaard, Annet Simons, Lucy A. Godley, David M. Ross, Devendra K. Hiwase, Jean Soulier, Anna L. Brown, Catherine L. Carmichael, Hamish S. Scott, Christopher N. Hahn

Blood (2024) 144 (17): 1765–1780.

https://doi.org/10.1182/blood.2024024607

Published: 2024

Includes: Supplemental data

Journal Articles

Identifying disease-modifying potential in myelofibrosis clinical trials

David M. Ross, Steven W. Lane, Claire N. Harrison

Blood (2024) 144 (16): 1679–1688.

https://doi.org/10.1182/blood.2024024220

Published: 2024

Journal Articles

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

Ilaria S. Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A. Saunders, Randall Grose, Chung H. Kok, Jane James, Molly Tolland, Jodi A. Braley, Haley K. Altamura, David T. Yeung, Susan Branford, Agnes S. M. Yong, Timothy P. Hughes, David M. Ross

Blood (2023) 142 (25): 2192–2197.

https://doi.org/10.1182/blood.2023021119

Published: 2023

Includes: Supplemental data

Journal Articles

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Blood (2023) 142 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2023-191986

Published: 2023

Journal Articles

Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis

Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampon, Hsin-An Hou, Grzegorz Helbig, Argiris S. Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, David M Ross

Blood (2023) 142 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2023-173942

Published: 2023

Journal Articles

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Claire N Harrison, David M. Ross, Lynette C.Y. Chee, Shuhying Tan, Marielle Wondergem, Timothy Devos, Christine Graham, Allie McGinty, Michael Pace, Hongying Wang, Ying Jiang, Suresh Bobba, Katie Louise Dawson, Christopher Rovaldi, Montagu Hankin, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2023-187099

Published: 2023

Journal Articles

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Susan Branford, Carol Wadham, Naranie Shanmuganathan, Adelina Fernandes, Nur Hezrin Shahrin, Jinghua Feng, John Toubia, Paul Wang, Chung Hoow Kok, Muneeza Maqsood, Verity Saunders, Rob King, Ming Lin, Rosalie Kenyon, Ilaria Stefania Pagani, David T Yeung, David M. Ross, Agnes S. M. Yong, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 447.

https://doi.org/10.1182/blood-2023-174425

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Lih En Hong, Chung Hoow Kok, Monika Kutyna, Joule J Li, Rakchha Chhetri, David M. Ross, Susan Branford, Hamish S Scott, Anna Brown, Christopher Norman Hahn, David T Yeung, Mrinal M. Patnaik, Mithun V Shah, Susanna Proudman, Mihir Wechalekar, Devendra Hiwase

Blood (2023) 142 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2023-190809

Published: 2023

Journal Articles

Phase 1/2a Trial of Bomedemstat with or without All- Trans Retinoic Acid (ATRA) in Advanced Myeloid Malignancies

David M. Ross, William S. Stevenson, Jake Shortt, Julian Cooney, Ian Lewis, Hugh Young Rienhoff Jr.

Blood (2023) 142 (Supplement 1): 6494.

https://doi.org/10.1182/blood-2023-180924

Published: 2023

Journal Articles

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Maha M Kamel, Monika Kutyna, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2023-188340

Published: 2023

Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Blood (2023) 142 (Supplement 1): 747.

https://doi.org/10.1182/blood-2023-179329

Published: 2023

Journal Articles

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Lynette C.Y. Chee, David M. Ross, Thomas Cluzeau, Shuhying Tan, Aristoteles Giagounidis, David Valcarcel, Montserrat Arnan, Maria Diez-Campelo, Christine Graham, Allie McGinty, Miranda Ross, Suresh Bobba, Wei Feng, Ying Jiang, Montagu Hankin, Christopher Rovaldi, Simon Cooper, Dena Grayson, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 1089.

https://doi.org/10.1182/blood-2023-186326

Published: 2023

Journal Articles

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Maria Diez-Campelo, David M. Ross, Aristoteles Giagounidis, Shuhying Tan, Thomas Cluzeau, Lynette C.Y. Chee, David Valcarcel, Montserrat Arnan, Christine Graham, Allie McGinty, Miranda Ross, Wei Feng, Ying Jiang, Suresh Bobba, Montagu Hankin, Christopher Rovaldi, Dena Grayson, Simon Cooper, Jen L. Salstrom

Blood (2023) 142 (Supplement 1): 196.

https://doi.org/10.1182/blood-2023-180974

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Monika Kutyna, Maha M Kamel, David M. Ross, Agnes S. M. Yong, Chun Yew Fong, Chloe Thompson-Peach, Steven W. Lane, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2023-179706

Published: 2023

Journal Articles

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Devendra Hiwase, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2023-179688

Published: 2023

Journal Articles

Single cells tell multiple tales in CML

David M. Ross

Blood (2023) 141 (22): 2668–2670.

https://doi.org/10.1182/blood.2023020165

Published: 2023

NARROW

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

Identifying disease-modifying potential in myelofibrosis clinical trials

Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis

Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Phase 1/2a Trial of Bomedemstat with or without All- Trans Retinoic Acid (ATRA) in Advanced Myeloid Malignancies

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche

Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Single cells tell multiple tales in CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only